Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galinpepimut S - SELLAS Life Sciences Group

Drug Profile

Galinpepimut S - SELLAS Life Sciences Group

Alternative Names: 3D-189; FPI-01; GPS-Memorial-Sloan-Kettering-Cancer-Center/Sellas-Life-Sciences-Group; SLS-001; WT-1 analog peptide vaccine-Memorial-Sloan-Kettering; WT-1-analogue-peptide-vaccine-Memorial-Sloan-Kettering; WT1 cancer vaccine - SELLAS Life Sciences; WT1 peptide vaccine - Memorial Sloan Kettering; WT1 vaccine - Memorial Sloan Kettering; WT1-cancer-vaccine-Memorial-Sloan-Kettering; WT1-peptide-vaccine-Sellas-Life-Sciences-Group; ZELTHERVA

Latest Information Update: 05 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer 3D Medicines; Bristol-Myers Squibb; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme Corp.; Sellas Life Sciences Group
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant-mesothelioma; Acute myeloid leukaemia; Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Cancer; Malignant-mesothelioma; Multiple myeloma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Fallopian tube cancer; Haematological malignancies; Peritoneal cancer

Most Recent Events

  • 03 Jan 2024 Sellas Life Sciences Group holds a Type C meeting with US FDA for GPS CMC program and commercial manufacturing and regulatory plans before January 2024
  • 27 Dec 2023 Efficacy data from a phase I trial in Malignant mesothelioma released by SELLAS Life Sciences Group
  • 04 Dec 2023 Sellas Life Sciences anticipates to meet with the Independent Data Monitoring Committee (IDMC) in the Q1 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top